Literature DB >> 20961695

Adoption of preoperative radiation therapy for rectal cancer from 2000 to 2006: a Surveillance, Epidemiology, and End Results Patterns-of-Care Study.

Raymond H Mak1, Ellen P McCarthy, Prajnan Das, Theodore S Hong, Harvey J Mamon, Karen E Hoffman.   

Abstract

PURPOSE: The German rectal study determined that preoperative radiation therapy (RT) as a component of combined-modality therapy decreased local tumor recurrence, increased sphincter preservation, and decreased treatment toxicity compared with postoperative RT for rectal cancer. We evaluated the use of preoperative RT after the presentation of the landmark German rectal study results and examined the impact of tumor and sociodemographic factors on receiving preoperative RT. METHODS AND MATERIALS: In total, 20,982 patients who underwent surgical resection for T3-T4 and/or node-positive rectal adenocarcinoma diagnosed from 2000 through 2006 were identified from the Surveillance, Epidemiology, and End Results tumor registries. We analyzed trends in preoperative RT use before and after publication of the findings from the German rectal study. We also performed multivariate logistic regression to identify factors associated with receiving preoperative RT.
RESULTS: Among those treated with RT, the proportion of patients treated with preoperative RT increased from 33.3% in 2000 to 63.8% in 2006. After adjustment for age; gender; race/ethnicity; marital status; Surveillance, Epidemiology, and End Results registry; county-level education; T stage; N stage; tumor size; and tumor grade, there was a significant association between later year of diagnosis and an increase in preoperative RT use (adjusted odds ratio, 1.26/y increase; 95% confidence interval, 1.23-1.29). When we compared the years before and after publication of the German rectal study (2000-2003 vs. 2004-2006), patients were more likely to receive preoperative RT than postoperative RT in 2004-2006 (adjusted odds ratio, 2.35; 95% confidence interval, 2.13-2.59). On multivariate analysis, patients who were older, who were female, and who resided in counties with lower educational levels had significantly decreased odds of receiving preoperative RT.
CONCLUSIONS: After the publication of the landmark German rectal study, there was widespread, rapid adoption of preoperative RT for locally advanced rectal cancer. However, preoperative RT may be underused in certain sociodemographic groups.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20961695     DOI: 10.1016/j.ijrobp.2010.03.056

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Authors:  Alissa Greenbaum; David R Martin; Thèrése Bocklage; Ji-Hyun Lee; Scott A Ness; Ashwani Rajput
Journal:  Clin Colorectal Cancer       Date:  2019-02-13       Impact factor: 4.481

2.  Post-chemoradiation anastomotic recurrence in locally advanced rectal cancer: no increased risk associated with distal margin.

Authors:  F A Calvo; F Rivas; C V Sole; M Gómez-Espí; R Herranz; E Del Valle; M Rodríguez; E Alvarez
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

3.  Comparison of treatment results between surgery alone, preoperative short-course radiotherapy, or long-course concurrent chemoradiotherapy in locally advanced rectal cancer.

Authors:  Chung-Hung Yeh; Miao-Fen Chen; Chia-Hsuan Lai; Wen-Shih Huang; Steve P Lee; Wen-Cheng Chen
Journal:  Int J Clin Oncol       Date:  2011-09-22       Impact factor: 3.402

4.  Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium.

Authors:  Mary E Charlton; Chi Lin; Dingfeng Jiang; Karyn B Stitzenberg; Thorvardur R Halfdanarson; Jane F Pendergast; Elizabeth A Chrischilles; Robert B Wallace
Journal:  Am J Clin Oncol       Date:  2013-12       Impact factor: 2.339

5.  Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.

Authors:  Anthony C Wong; Shannon Stock; Deborah Schrag; Katherine L Kahn; Talya Salz; Mary E Charlton; Selwyn O Rogers; Karyn A Goodman; Nancy L Keating
Journal:  J Oncol Pract       Date:  2014-07-01       Impact factor: 3.840

6.  Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium.

Authors:  Mary E Charlton; Karyn B Stitzenberg; Chi Lin; Jennifer A Schlichting; Thorvardur R Halfdanarson; Grelda Yazmin Juarez; Jane F Pendergast; Elizabeth A Chrischilles; Robert B Wallace
Journal:  J Oncol Pract       Date:  2015-06-16       Impact factor: 3.840

7.  Neoadjuvant radiotherapy for rectal cancer: adherence to evidence-based guidelines in clinical practice.

Authors:  Timothy L Fitzgerald; Tithe Biswas; Kevin O'Brien; Emmanuel E Zervos; Jan H Wong
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

8.  Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service.

Authors:  E J A Morris; P J Finan; K Spencer; I Geh; A Crellin; P Quirke; J D Thomas; S Lawton; R Adams; D Sebag-Montefiore
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-02-28       Impact factor: 4.126

9.  Gender differences in stage at diagnosis and preoperative radiotherapy in patients with rectal cancer.

Authors:  Cristina Sarasqueta; Mª Victoria Zunzunegui; José María Enríquez Navascues; Arrate Querejeta; Carlos Placer; Amaia Perales; Nerea Gonzalez; Urko Aguirre; Marisa Baré; Antonio Escobar; José María Quintana
Journal:  BMC Cancer       Date:  2020-08-14       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.